CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 265 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01368042
NCT01368042N/ACompleted
CompareCT.gov

Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe)

AbbVie (prior sponsor, Abbott)·observational·Posted Jun 7, 2011·Updated Aug 1, 2014

In Brief

An observational study for Chronic Kidney Disease and Secondary Hyperparathyroidism. Completed, enrolled 265 participants across 11 sites.

Detailed Summary

The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol intravenous (iv).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Secondary Hyperparathyroidism
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2011
Enrollment StartAug 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.1 years ago